HC Wainwright Brokers Lower Earnings Estimates for TNYA

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Analysts at HC Wainwright decreased their Q2 2025 earnings per share estimates for shares of Tenaya Therapeutics in a research report issued on Thursday, May 8th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.17) for the quarter, down from their previous forecast of ($0.14). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Tenaya Therapeutics’ Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.69) EPS, FY2026 earnings at ($0.66) EPS, FY2027 earnings at ($0.62) EPS and FY2028 earnings at ($0.67) EPS.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.06).

Several other research firms have also recently issued reports on TNYA. Chardan Capital reiterated a “buy” rating and issued a $9.00 price objective on shares of Tenaya Therapeutics in a report on Friday, May 9th. Morgan Stanley cut their price target on shares of Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, March 12th. Finally, Canaccord Genuity Group dropped their price target on Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating on the stock in a report on Thursday, March 13th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $6.25.

Tenaya Therapeutics Stock Down 4.1%

Shares of TNYA opened at $0.39 on Monday. The firm has a market capitalization of $34.54 million, a PE ratio of -0.27 and a beta of 2.99. The firm has a 50-day moving average price of $0.53 and a 200 day moving average price of $1.35. Tenaya Therapeutics has a 52-week low of $0.36 and a 52-week high of $4.78.

Insider Activity at Tenaya Therapeutics

In related news, major shareholder Group Gp Lp Column III bought 35,714,284 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was acquired at an average cost of $0.70 per share, with a total value of $24,999,998.80. Following the acquisition, the insider now owns 49,313,559 shares in the company, valued at approximately $34,519,491.30. This represents a 262.62% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 19,621 shares of company stock worth $10,595 in the last 90 days. 32.76% of the stock is owned by company insiders.

Institutional Trading of Tenaya Therapeutics

Several hedge funds have recently modified their holdings of TNYA. Woodline Partners LP acquired a new position in Tenaya Therapeutics in the fourth quarter worth $28,000. Commerce Bank bought a new position in shares of Tenaya Therapeutics in the fourth quarter valued at about $29,000. Mariner LLC acquired a new position in Tenaya Therapeutics during the 4th quarter worth about $30,000. Ground Swell Capital LLC bought a new stake in Tenaya Therapeutics during the 4th quarter worth about $32,000. Finally, Hsbc Holdings PLC bought a new stake in Tenaya Therapeutics during the 4th quarter worth about $45,000. Institutional investors and hedge funds own 90.54% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.